Last reviewed · How we verify
A Phase 1a/b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of FhCMB HAI-05, a Recombinant Hemagglutinin (rHA) Vaccine Derived From Influenza A/Indonesia/05/2005 (H5N1), in Healthy Adults 18 to 49 Years
The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1 Vaccine in healthy adults.
Details
| Lead sponsor | Fraunhofer, Center for Molecular Biotechnology |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | 2010-11 |
| Completion | 2011-07 |
Conditions
- Healthy
Interventions
- HAI-05 Influenza Vaccine
- Saline
Primary outcomes
- safety — 200 days
Countries
United States